DeepMed Research

BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug

Phase 2

Completed

Conditions: End Stage Renal Disease Requiring Hemodialysis

Interventions: Drug: Fesomersen sodium (BAY2976217)
Drug: Placebo

First Posted Date: 2020-09-01

Last Posted Date: 2023-07-03

Lead Sponsor: Bayer

Target Recruit Count: 307

Registration Number: NCT04534114

Locations: 🇨🇦
Unity Health Toronto: St. Michael's Hospital, Toronto, Ontario, Canada
🇺🇸
Desert Cities Dialysis-Amethyst & Desert Cities Dialysis, Victorville, California, United States
🇺🇸
Fresenius Kidney Care Clovis, Clovis, California, United States

and more 66 locations

Study to Gather Information on the Acceptability of a New Flavor System With Increasing Levels of 2, 4, 6 g or Higher of Mannitol for PEG 3350 in Subjects Having Infrequent Bowel Movements.

Phase 4

Completed

Conditions: Constipation

Interventions: Drug: Polyethylene glycol (MiraLAX, BAY81-8430)
Drug: Mannitol

First Posted Date: 2020-09-01

Last Posted Date: 2020-11-12

Lead Sponsor: Bayer

Target Recruit Count: 50

Registration Number: NCT04534465

Locations: 🇺🇸
Merck Consumer Center, Memphis, Tennessee, United States

Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)

Phase 3

Completed

Conditions: Hypersensitivity

Interventions: Drug: Butenafine HCl 1% (BAY1896425)
Drug: Positive Control-Sodium lauryl sulfate (SLS)
Other: Negative Control

First Posted Date: 2020-08-31

Last Posted Date: 2020-09-25

Lead Sponsor: Bayer

Target Recruit Count: 32

Registration Number: NCT04531813

Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants

Phase 3

Completed

Conditions: Dermatitis, Photoallergic

Interventions: Drug: Butenafine HCl 1% (BAY1896425) - Induction Phase
Drug: Butenafine HCl 1% (BAY1896425) - Challenge Phase

First Posted Date: 2020-08-31

Last Posted Date: 2020-11-16

Lead Sponsor: Bayer

Target Recruit Count: 137

Registration Number: NCT04532164

Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects

Phase 3

Completed

Conditions: Dermatitis, Phototoxic

Interventions: Drug: Butenafine HCl 1% (BAY1896425)

First Posted Date: 2020-08-28

Last Posted Date: 2020-11-13

Lead Sponsor: Bayer

Target Recruit Count: 32

Registration Number: NCT04531527

Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)

Phase 3

Completed

Conditions: Hypersensitivity

Interventions: Drug: Butenafine HCl 1% (BAY1896425)

First Posted Date: 2020-08-28

Last Posted Date: 2020-11-17

Lead Sponsor: Bayer

Target Recruit Count: 225

Registration Number: NCT04531540

A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)

Completed

Conditions: Myopic Choroidal Neovascularization

Interventions: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

First Posted Date: 2020-08-24

Last Posted Date: 2023-06-18

Lead Sponsor: Bayer

Target Recruit Count: 28

Registration Number: NCT04524910

Locations: 🇨🇦
Many Locations, Multiple Locations, Canada

Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis

Phase 2

Completed

Conditions: End-stage Renal Disease
Prevention of Thromboembolic Events
Hemodiafiltration
Hemodialysis

Interventions: Drug: Placebo
Drug: BAY1213790 (Osocimab)

First Posted Date: 2020-08-21

Last Posted Date: 2023-07-21

Lead Sponsor: Bayer

Target Recruit Count: 704

Registration Number: NCT04523220

Locations: 🇺🇸
East L.A. Dialysis Center, Los Angeles, California, United States
🇵🇱
Wojewodzki Szpital Zespolony, Kielce, Poland
🇬🇷
HIPPOKRATION General Hospital of Athens, Athens, Greece

and more 145 locations

A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones

Phase 1

Active, not recruiting

Conditions: Bone Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)

First Posted Date: 2020-08-20

Last Posted Date: 2025-05-08

Lead Sponsor: Bayer

Target Recruit Count: 46

Registration Number: NCT04521361

Locations: 🇫🇷
Institut Claudius Regaud - iUCT Oncopole, Toulouse Cedex 9, France
🇮🇱
Rambam Health Corporation, Haifa, Israel
🇦🇹
Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, Austria

and more 9 locations

Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

Recruiting

Conditions: Neovascular Glaucoma

Interventions: Drug: Aflibercept (Eylea, BAY86-5321)

First Posted Date: 2020-08-19

Last Posted Date: 2025-05-20

Lead Sponsor: Bayer

Target Recruit Count: 480

Registration Number: NCT04519619

Locations: 🇯🇵
Many locations, Multiple Locations, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy